COMMUNIQUÉS West-GlobeNewswire

Coherus Oncology to Participate in Upcoming Investor Conferences
23/02/2026
REDWOOD CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will be presenting during upcoming conferences. The presentations will be accessible [...]
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
23/02/2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” [...]
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a [...]
SafeSpace Global Corporation Transitions from Pre-Revenue to Active Revenue Generation with Eight Contracted Senior Living Facility Installations
23/02/2026
Company Begins Recurring Monthly Revenue Stream in February 2026 through Deployment of AI-powered, Privacy-Aware Technology that Replaces Wearables and Loud Alarms with Proactive and Dignified Resident Safety KNOXVILLE [...]
Nucleus Upgrades Preview, The First True Glimpse of Your Future Child
23/02/2026
Couples can now model 100 potential children across rare and common diseases, offering the most complete picture of inheritance yet. NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nucleus Genomics today introduced Preview [...]
Editas Medicine to Participate in Upcoming Investor Conferences
23/02/2026
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that [...]
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
23/02/2026
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making [...]
Neutrolis Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors as Executive Director
23/02/2026
Dr. Dolsten, former Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer, brings leadership experience spanning approximately 50 regulatory approvals and over $100 billion in [...]
Solana Company (NASDAQ: HSDT) Announces Plan for the Pacific Backbone, a High-Speed Infrastructure Buildout for Solana
23/02/2026
Deployment to be focused on Asia-Pacific region to capitalize on fast-growing wealth accumulation, cross-border payments, and institutional adoption of digital assets Expansion planned to enable Solana Company to [...]
J-Star Signs Exclusive Distribution Agreement with PSSB
23/02/2026
TAICHUNG CITY, Taiwan, Feb. 23, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions serving diverse [...]
Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
23/02/2026
Up to 733% Greater Potency Across 11 Key Nutrients, Including New Saffron Nootropic and Bioactive Vitamin Forms Two New Flavours — Mango + Passionfruit and Lemon + Orange Same Price for New and Existing Customers Full [...]
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer
23/02/2026
OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM’ [...]
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
23/02/2026
Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and genomics TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
23/02/2026
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 [...]
Blue Genes Partners with RxSense to Deliver Actionable PGx at the Point of Adjudication
23/02/2026
The new partnership will enhance pharmacy benefit decision-making by embedding real-time genetic intelligence into adjudication workflows SCOTTSDALE, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Blue Genes today announced a [...]
ICU Medical to Participate in Upcoming Investor Conferences
23/02/2026
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the [...]
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
23/02/2026
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 GLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the [...]
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
23/02/2026
HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and [...]
Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference
23/02/2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced participation in one-on-one [...]

Pages